Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice

Cancer Research

Volumn 63, Issue 9, 2003, Pages 2096-2102

  Yonou, Hiroyuki ^a,c   Kanomata, Naoki ^a   Goya, Masato ^a   Kamijo, Tomoyuki ^a   Yokose, Tomoyuki ^a   Hasebe, Takahiro ^a   Nagai, Kanji ^b   Hatano, Tadashi ^c   Ogawa, Yoshihide ^c   Ochiai, Atsushi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BONE TUMOR; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MORPHOMETRICS; MOUSE; MOUSE STRAIN; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; SCID MOUSE; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME;

ANIMALS; BONE NEOPLASMS; CELL DIVISION; GLYCOPROTEINS; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; OSTEOPROTEGERIN; PROSTATIC NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037728969     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Abrams, H. L., Spiro, R., and Goldstein, N. Metastases in carcinoma: analysis of 1000 autopsied cases. Cancer (Phila.), 3: 74-85, 1950.
2. Linehan, W. M., Long, J. P., Steeg, P. S., and Gnarra, J. R. Metastatic models and molecular genetics of prostate cancer. J. Natl. Cancer Inst., 84: 914-915, 1992.
3. Clarke, N. W., McClure, J., and George, N. J. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br. J. Urol., 69: 64-70, 1992.
4. Charhon, S. A., Chapuy, M. C., Delvin, E. E., Valentin-Opran, A., Edouard, C. M., and Meunier, P. J. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer (Phila.), 51: 918-924, 1983.
5. Urwin, G. H., Percival, R. C., Harris, S., Beneton, M. N., Williams, J. L., and Kanis, J. A. Generalised increase in bone resorption in carcinoma of the prostate. Br. J. Urol., 57: 721-723, 1985.
6. Percival, R. C., Urwin, G. H., Harris, S., Yates, A. J., Williams, J. L., Beneton, M., and Kanis, J. A. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur. J. Surg. Oncol., 13: 41-49, 1987.
7. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N., and Suda, T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA, 95: 3597-3602, 1998.
8. Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., and Galibert, L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (Lond.), 390: 175-179, 1997.
9. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J., and Boyle, W. J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93: 165-176, 1998.
10. Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., Morinaga, T., and Higashio, K. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun., 253: 395-400, 1998.
11. Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Luthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H. L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T. M., Hill, D., Pattison, W., Campbell, P., and Boyle, W. J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 89: 309-319, 1997.
12. Tsuda, E., Goto, M., Mochizuki, S., Yano, K., Kobayashi, F., Morinaga, T., and Higashio, K. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun., 234: 137-142, 1997.
13. Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., Kanno, T., Murakami, A., Tsuda, E., Morinaga, T., and Higashio, K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology, 139: 1329-1337, 1998.
14. Brown, J. M., Corey, E., Lee, Z. D., True, L. D., Yun, T. J., Tondravi, M., and Vessella, R. L. Osteoprotegerin and rank ligand expression in prostate cancer. Urology, 57: 611-616, 2001.
15. Yonou, H., Yokose, T., Kamijo, T., Kanomata, N., Hasebe, T., Nagai, K., Hatano, T., Ogawa, Y., and Ochiai, A. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res., 61: 2177-2182, 2001.
16. Horoszewicz, J. S. LNCaP model of human prostatic carcinoma. Cancer Res., 43: 1809-1818, 1983.
17. Kyoizumi, S., Baum, C. M., Kaneshima, H., McCune, J. M., Yee, E. J., and Namikawa, R. Implantation and maintenance of functional human bone marrow in SCID-hu mice. Blood, 79: 1704-1711, 1992.
18. Yamaguchi, K., Kinosaki, M., Goto, M., Kobayashi, F., Tsuda, E., Morinaga, T., and Higashio, K. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J. Biol. Chem., 273: 5117-5123, 1998.
19. Hsu, S. M., Raine, L., and Fanger, H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem., 29: 577-580, 1981.
20. Hiraga, T., Nakajima, T., and Ozawa, H. Bone resorption induced by a metastatic human melanoma cell line. Bone, 16: 349-356, 1995.
21. Vinholes, J., Coleman, R., and Eastell, R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat. Rev., 22: 289-331, 1996.
22. Berruti, A., Piovesan, A., Torta, M., Raucci, C. A., Gorzegno, G., Paccotti, P., Dogliotti, L., and Angeli, A. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br. J. Cancer, 73: 1581-1587, 1996.
23. Nielsen, O. S., Munro, A. J., and Tannock, I. F. Bone metastases: pathophysiology and management policy. J. Clin. Oncol., 9: 509-524, 1991.
24. Zhang, J., Dai, J., Qi, Y., Lin, D. L., Smith, P., Strayhom, C., Mizokami, A., Fu, Z., Westman, J., and Keller, E. T. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Investig., 107: 1235-1244, 2001.
25. Sasaki, A., Williams, P. J., Mundy, G. R., and Yoneda, T. Osteolysis and tumor growth are enhanced in sites of increased bone turnover in vivo. J. Bone Miner. Res., 9: S294, 1994.
26. Hauschka, P. V., Mavrakos, A. E., Iafrati, M. D., Doleman, S. E., and Klagsbrun, M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J. Biol. Chem., 261: 12665-12674, 1986.
27. Pfeilschifter, J., and Mundy, G. R. Modulation of type β transforming growth factor activity in bone cultures by osteotropic hormones. Proc. Natl. Acad. Sci. USA, 84: 2024-2028, 1987.
28. Paget, S. The distribution of secondary growths in cancer of the breast. Lancet, 1: 571-573, 1889.
29. Mundy, G. R., and Yoneda, T. Facilitation and suppression of bone metastasis. Clin. Orthop., 312: 34-44, 1995.
30. Shalhoub, V., Faust, J., Boyle, W. J., Dunstan, C. R., Kelley, M., Kaufman, S., Scully, S., Van, G., and Lacey, D. L. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. J. Cell. Biochem., 72: 251-261, 1999.
31. Burgess, T. L., Qian, Y., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., Hu, S., and Lacey, D. L. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell. Biol., 145: 527-538, 1999.
32. Akatsu, T., Murakami, T., Nishikawa, M., Ono, K., Shinomiya, N., Tsuda, E., Mochizuki, S., Yamaguchi, K., Kinosaki, M., Higashio, K., Yamamoto, M., Motoyoshi, K., and Nagata, N. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem. Biophys. Res. Commun., 250: 229-234, 1998.
33. Fuller, K., Wong, B., Fox, S., Choi, Y., and Chambers, T. J. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J. Exp. Med., 188: 997-1001, 1998.
34. Jimi, E., Akiyama, S., Tsurukai, T., Okahashi, N., Kobayashi, K., Udagawa, N., Nishihara, T., Takahashi, N., and Suda, T. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J. Immunol., 163: 434-442, 1999.
35. Capparelli, C., Kostenuik, P. J., Morony, S., Starnes, C., Weimann, B., Van, G., Scully, S., Qi, M., Lacey, D. L., and Dunstan, C. R. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res., 60: 783-787, 2000.
36. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., and Goodwin, R. G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3: 673-682, 1995.
37. Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., Dodds, R. A., James, I. E., Rosenberg, M., Lee, J. C., and Young, P. R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem., 273: 14363-14367, 1998.
38. Holen, I., Croucher, P. I., Hamdy, F. C., and Eaton, C. L. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res., 62: 1619-1623, 2002.
39. Truneh, A., Sharma, S., Silverman, C., Khandekar, S., Reddy, M. P., Deen, K. C., McLaughlin, M. M., Srinivasula, S. M., Livi, G. P., Marshall, L. A., Alnemri, E. S., Williams, W. V., and Doyle, M. L. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J. Biol. Chem., 275: 23319-23325, 2000.
40. Kostenuik, P. J., and Shalhoub, V. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr. Pharm. Des., 7: 613-635, 2001.
41. Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., and Dunstan, C. R. The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res., 16: 348-360, 2001.
42. Body, J. J., Lipton, A., Coleman, R. E., Theriault, R., Ralston, S. H., Eisenberg, P., Dunstan, C. R., and Bekker, P. J. An OPG construct decreases bone resorption profoundly in breast cancer bone metastases. J. Bone Miner. Metab., 19(Suppl.): 51, 2001.